Symptoms of CHF include poor feeding, shortness of breath, diaphoresis during feeding, and poor weight gain
Localized pain or irritation at injection site Mild gastrointestinal discomfort Headache or lightheadedness Temporary skin rash 8.2 Less Common and Serious Side Effects Although infrequent, more serious reactions have been reported
More than 1,000 participants took part in this trial, and the results were striking: 10,800 FU/day of nattokinase (not the traditionally recommended 2,000 FU) produced meaningful improvements across cardiovascular markers, including lipids, carotid intima-media thickness, and plaque size
Facilitating effective fat loss and maintenance Controlling blood sugar and preventing diabetes in patients at risk Lowering blood pressure Improving lipids (achieving a healthy blood lipid profile) Reducing risk of heart disease and kidney disease "These are not amenities
2019;140(11):e596-e646.
Consolidation and verticalization continue